Comparative Pharmacology
Head-to-head clinical analysis: INFLAMASE FORTE versus PRED FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFLAMASE FORTE versus PRED FORTE.
INFLAMASE FORTE vs PRED FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Corticosteroid that binds to glucocorticoid receptors, causing inhibition of phospholipase A2, arachidonic acid release, and synthesis of inflammatory mediators. Reduces inflammation by suppressing leukocyte infiltration and cytokine production.
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
1-2 drops in the conjunctival sac every 1-2 hours during the day and every 4 hours at night initially, then taper to every 4-8 hours as inflammation resolves. Severe cases may require hourly dosing.
None Documented
None Documented
Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
2-3 hours (terminal) after IV administration; for topical ophthalmic use, systemic half-life is similar but local ocular half-life is prolonged due to corneal reservoir.
Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination.
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 80% of elimination, with biliary/fecal elimination <20%.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid